Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA3 | P07451 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233534 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL3054555 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL1948713 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL5085490 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL2796068 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL2031871 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL4755739 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL4755756 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL4754026 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL2796425 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948926-A | Mitochondrion-targeted cabazitaxel prodrug and preparation method and application thereof | 浙江大学医学院附属第一医院 | 2022-08-30 | — | — | CN | claimed |
| CN-109715704-A | The method for preparing polymer film | 巴斯夫欧洲公司 | 2019-05-03 | — | — | CN | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
| WO-2023181977-A1 | ELECTROCONDUCTIVE POLYMER COMPOSITION AND USE THEREOF | 東ソー株式会社 | 2023-09-28 | — | — | WO | disclosed |
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| CN-116514161-A | Nanoparticle, nanoparticle dispersion liquid, and method for producing nanoparticle | 东京应化工业株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-116515023-A | Composition and cured product | 东京应化工业株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-114948926-A | Mitochondrion-targeted cabazitaxel prodrug and preparation method and application thereof | 浙江大学医学院附属第一医院 | 2022-08-30 | — | — | CN | disclosed |
| CN-110325358-A | Laminated material containing metal and daiamid composition | 巴斯夫欧洲公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-109937226-A | Polymer film containing at least one copolyamide of diamine, dicarboxylic acid and dimer acid | 巴斯夫欧洲公司 | 2019-06-25 | — | — | CN | disclosed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | disclosed |
| EP-0228192-A2 | Renin-inhibitory oligopeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| US-4659516-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-21 | — | — | US | disclosed |
| US-4644046-A | BLEND OF SILICON CONTAINING POLYAMINE, POLYSILOXANE, AND DIISOCYNATE GROUP | TEIJIN LIMITED (JP) | 1987-02-17 | — | — | US | disclosed |
| EP-0138504-A2 | Steroid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-04-24 | — | — | EP | disclosed |
| US-4493714-A | SILICON CONTAINING POLYUREAS | TEIJIN LIMITED (JP) | 1985-01-15 | — | — | US | disclosed |
| EP-0094050-A2 | Ultrathin film, process for production thereof, and use thereof for concentrating a specified gas in a gaseous mixture | TEIJIN LIMITED (JP) | 1983-11-16 | — | — | EP | disclosed |
| US-4100089-A | High-voltage insulating material comprising anti-tracking and erosion inhibiting compounds with insulating polymers | RAYCHEM CORPORATION (US) | 1978-07-11 | — | — | US | disclosed |
| US-3976767-A | Purification of hepatitis B surface antigen by chromatography on agarose containing aminoalkyl residues | THE NEW YORK BLOOD CENTER (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | CD63, NIBAN2, ZRANB2 | DNM1 463/4885CA12 944/4885CA1 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.